Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease

被引：0
|
作者：
Gkiouras, Konstantinos [1 ]
Grammatikopoulou, Maria G. [1 ,2 ]
Simopoulou, Theodora [1 ]
Daniil, Zoe [3 ]
Bogdanos, Dimitrios P. [1 ]
机构：
[1] Univ Thessaly, Dept Rheumatol & Clin Immunol, Fac Med, Sch Hlth Sci, Larisa, Greece
[2] Int Hellen Univ, Dept Nutr Sci & Dietet, Fac Hlth Sci, Alexander Campus, Thessaloniki, Greece
[3] Univ Thessaly, Dept Resp, Med Dept, Fac Med, Larisa, Greece
来源：
CLINICAL RHEUMATOLOGY | 2021年 / 40卷 / 08期
关键词：
METAANALYSES;
D O I：
10.1007/s10067-021-05845-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3379 / 3380
页数：2
相关论文
共 50 条
  • [11] Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease
    Kim, Grace Hyun J.
    Tashkin, Donald P.
    Lo, Pechin
    Brown, Matthew S.
    Volkmann, Elizabeth R.
    Gjertson, David W.
    Khanna, Dinesh
    Elashoff, Robert M.
    Tseng, Chi-Hong
    Roth, Michael D.
    Goldin, Jonathan G.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (02) : 316 - 325
  • [12] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168
  • [13] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [14] Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis
    Schneider, Udo
    Siegert, Elise
    Glaser, Sven
    Kruger, Klaus
    Krause, Andreas
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (09): : 868 - 878
  • [15] Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Sim, Myung
    Li, Ning
    Khanna, Dinesh
    Roth, Michael D.
    Clements, Philip J.
    Hoffmann-Vold, Anna-Maria
    Furst, Daniel E.
    Kim, Grace
    Goldin, Jonathan
    Elashoff, Robert M.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (10) : 1316 - 1325
  • [16] Treatment of systemic sclerosis with severe interstitial lung disease (ILD) unresponsive to cyclophosphamide (CYC) with mycophenolate mofetil (MMIT).
    Mouthon, L
    Valeyre, D
    Brauner, M
    Lamberto, C
    André, MH
    Mahr, A
    Guillevin, L
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S559 - S559
  • [17] Difficulties in diagnosis of systemic sclerosis-related interstitial lung disease
    Vrancken, Anniek
    De langhe, Ellen
    Westhovens, Rene
    Yserbyt, Jonas
    Cottin, Vincent
    Wuyts, Wim
    RESPIROLOGY CASE REPORTS, 2015, 3 (03): : 99 - 101
  • [18] MYCOPHENOLATE MOFETIL VERSUS CYCLOPHOSPHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE IN A REAL LIFE SCENARIO
    Fretheim, H.
    Midtvedt, O.
    Volkmann, E.
    Garen, T.
    Lund, M. B.
    Aalokken, T.
    Molberg, O.
    Hoffmann-Vold, A. -M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 106 - 106
  • [19] Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil
    Takada, Toshinori
    Aoki, Ami
    Shima, Kenjiro
    Kikuchi, Toshiaki
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1242 - 1246
  • [20] COST EFFECTIVENESS OF MOFETIL MYCOPHENOLATE COMPARED WITH CYCLOPHOSPHAMIDE FOR THE TREATMENT OF SYSTEMIC SCLEROSIS IN PATIENTS WITH DIFFUSE INTERSTITIAL PULMONARY DISEASE IN COLOMBIA
    Paola Saavedra, Ginna
    Bello Gualtero, Juan Manuel
    Quitian Reyes, Hoover
    Buitrago-Gutierrez, Giancarlo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S8 - S8
12345